The diagnosis and management of von Willebrand Disease in Canada

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 5, 2011, Pages 522-527

  James, Paula D ^a   Lillicrap, David P ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Association of Hemophilia Clinic Directors of Canada; diagnosis; management; von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; DESMOPRESSIN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; TRANEXAMIC ACID;

ARTICLE; ASSOCIATION OF HEMOPHILIA CLINIC DIRECTORS OF CANADA; BLEEDING; CANADA; CANADIAN ASSOCIATION OF NURSES IN HEMOPHILIA CARE; CANADIAN HEMOPHILIA SOCIETY; CLINICAL ASSESSMENT; DIAGNOSTIC TEST; ENDOMETRIUM ABLATION; GENETIC SCREENING; GYNECOLOGY; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEMOPHILIA; HEMOPHILIA A; HUMAN; HYSTERECTOMY; MEDICAL RESEARCH; MENORRHAGIA; PATIENT CARE; PHENOTYPE; PHYSIOTHERAPIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIAL WORKER; VON WILLEBRAND DISEASE;

CANADA; COMPREHENSIVE HEALTH CARE; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; GENETIC TESTING; HEMORRHAGIC DISORDERS; HEMOSTATICS; HUMANS; PRACTICE GUIDELINES AS TOPIC; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 81755171909     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1281038     Document Type: Article

References (31)

1. Statistics Canada. Available at: http://www.statcan.gc.ca/ig-gi/pop-ca- eng.htm Stats Canada. Accessed January 4, 2011
2. Bloom AL. von Willebrand factor: clinical features of inherited and acquired disorders. Mayo Clin Proc 1991 66 7 743-751
3. Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010 8 1 213-216
4. Health Canada. Available at: http://www.hc-sc.gc.ca/hcs-sss/medi-assur/ index-eng.php Accessed January 4, 2011
5. Canadian Hemophilia Society. Available at: http://www.hemophilia.ca/ Accessed January 4, 2011
6. Association of Hemophilia Clinic Directors of Canada. Available at: http://www.ahcdc.ca/documents/CanadianHemophiliaStandardsFirstEdition070612-1. pdf Accessed January 4, 2011
7. James PD, O'Brien LA, Hegadorn CA et al. A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exons. Blood 2004 104 9 2739-2745 (Pubitemid 39434956)
8. James PD, Paterson AD, Notley C et al, Association of Hemophilia Clinic Directors of Canada. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006 4 4 783-792
9. James PD, Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007 109 1 145-154 (Pubitemid 46053055)
10. James PD, Notley C, Hegadorn C et al, Association of Hemophilia Clinic Directors of Canada. Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study. J Thromb Haemost 2007 5 9 1914-1922 (Pubitemid 47288950)
11. Jackson SC, Sinclair GD, Cloutier S, Duan Z, Rand ML, Poon MC. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 2009 113 14 3348-3351
12. Othman M, Hamilton A. Platelet-type von Willebrand disease: results of a worldwide survey from the Canadian PT-VWD project. Acta Haematol 2010 123 2 126-128
13. Chen CI, Federici AB, Cramer EM et al. Studies of multimers in patients with von Willebrand disease and platelet von Willebrand factor deficiency. Br J Haematol 1998 103 1 20-28 (Pubitemid 28470794)
14. Alhumood SA, Devine DV, Lawson L, Nantel SH, Carter CJ. Idiopathic immune-mediated acquired von Willebrand's disease in a patient with angiodysplasia: demonstration of an unusual inhibitor causing a functional defect and rapid clearance of von Willebrand factor. Am J Hematol 1999 60 2 151-157 (Pubitemid 29047438)
15. Pruss CM, Notley CR, Hegadorn CA, O'Brien LA, Lillicrap D. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor. Br J Haematol 2008 143 4 552-558
16. Berber E, James PD, Hough C, Lillicrap D. An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution. J Thromb Haemost 2009 7 10 1672-1679
17. Chegeni R, Vickars L, Favaloro EJ, Lillicrap D, Othman M. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease. Thromb Res 2011 127 2 161-166
18. Golder M, Pruss CM, Hegadorn C et al. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions. Blood 2010 115 23 4862-4869
19. Barr RD, Sek J, Horsman J et al. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol 2003 73 2 108-114 (Pubitemid 36578432)
20. Smiley RK, Tittley P, Rock G. Studies on the prolonged bleeding time in von Willebrand's disease. Thromb Res 1989 53 5 417-426 (Pubitemid 19114475)
21. Rand ML, Carcao MD, Blanchette VS. Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost 1998 24 6 523-529 (Pubitemid 29095425)
22. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/ von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002 87 2 224-230 (Pubitemid 34139857)
23. Revel-Vilk S, Schmugge M, Carcao MD, Blanchette P, Rand ML, Blanchette VS. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol 2003 25 11 874-879 (Pubitemid 37413837)
24. Demers C, Derzko C, David M, Douglas J, Society of Obstetricians and Gynecologists of Canada. Gynaecological and obstetric management of women with inherited bleeding disorders. J Obstet Gynaecol Can 2005 27 7 707-732
25. Carcao MD, Seary ME, Casas M, Winter L, Stain AM, Judd P. Dental disease in type 3 von Willebrand disease: a neglected problem. Haemophilia 2010 16 6 943-948
26. Bowman M, Hopman WM, Rapson D, Lillicrap D, Silva M, James P. A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population. Pediatr Blood Cancer 2010 55 1 171-173
27. Dean JA, Blanchette VS, Carcao MD et al. von Willebrand disease in a pediatric-based populationcomparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000 84 3 401-409
28. Bowman M, Mundell G, Grabell J et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008 6 12 2062-2066
29. Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009 7 8 1418-1421
30. Biss TT, Blanchette VS, Clark DS et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010 8 5 950-956
31. Association of Hemophilia Clinic Directors of Canada. Available at: http://www.ahcdc.ca/publications-and-guidelines/vonWillebrand'sdisease Accessed January 4, 2011